Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. - Wikidata - awgldk - TriplyDB

Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

http://www.wikidata.org/entity/Q34035546

about

The limits of oral therapy in pulmonary arterial hypertension management Interdisciplinary networks for the treatment of childhood pulmonary vascular disease: what pulmonary hypertension doctors can learn from pediatric oncologists Molecular mechanisms of pulmonary arterial remodeling Drug treatment of pulmonary hypertension in children Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions Novel signaling pathways in pulmonary arterial hypertension (2015 Grover Conference Series)Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension.Pediatric pulmonary arterial hypertension.Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension.Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series.Identifying "super responders" in pulmonary arterial hypertension.The cancer theory of pulmonary arterial hypertension.PK10453, a nonselective platelet-derived growth factor receptor inhibitor, prevents the progression of pulmonary arterial hypertension.Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.Bone marrow-derived vascular modulatory cells in pulmonary arterial hypertension.Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies.Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension.New trial designs and potential therapies for pulmonary artery hypertension.Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.An update on cardio-oncology.Imatinib in pulmonary arterial hypertension: c-Kit inhibition Sex differences in response to tadalafil in pulmonary arterial hypertension.Deficiency of Akt1, but not Akt2, attenuates the development of pulmonary hypertension.Targeting receptor tyrosine kinases and their downstream signaling with cell-penetrating peptides in human pulmonary artery smooth muscle and endothelial cells Hyperplastic Growth of Pulmonary Artery Smooth Muscle Cells from Subjects with Pulmonary Arterial Hypertension Is Activated through JNK and p38 MAPK.Progress in the understanding and management of pulmonary arterial hypertension.Current clinical management of pulmonary arterial hypertension Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension.Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome.Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.Whither Anticoagulation in Pulmonary Arterial Hypertension? Conflicting Evidence REVEALed.Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells.PDGF-dependent β-catenin activation is associated with abnormal pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group repor Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

P2860

Q26773209-8BE1E782-9782-4A0B-A0AD-82F1FE812A96 Q26860314-3C6D6C55-FC96-4E73-B58A-7967C77F4D09 Q26991806-6663CD90-2B91-4CFD-85F4-FA83BB8731F9 Q26996078-2440B52F-B20D-42AB-B87C-F0CC47DAA73A Q27023074-AF9F305F-0EF7-44A0-A11B-FA0FB36ABE66 Q28078946-7988D383-48E9-4003-B9A6-2DEB369F4278 Q28078976-6FAE5A8C-FA52-4FC4-A905-4A6303C9CA84 Q30884142-7108BAD6-FD44-4B65-9D30-59D3E2997622 Q30936117-0E5F303C-3EF0-4CD3-A145-7E6B4F4F0472 Q32884516-38CEAA67-CE98-4DA7-BBBE-E2708C4EBFAF Q33163446-8A5EC6E8-E64F-485A-9882-8AD92DC353B8 Q33737242-E9A0C61A-CD2D-4508-8877-9CFEC8A80951 Q33738626-A68E32D6-311D-4152-985B-A23BE00DC199 Q33788452-37C2F870-0302-40EC-96B5-39468AAE1EC8 Q33788493-2AC8AAE9-B443-473B-B2E9-E3438D88FB52 Q33805920-AD0FCA16-050E-4CEA-95A0-DC67CEB12BC6 Q33806121-A48664FC-DA03-4CB9-A700-6BE5B605E9DE Q33806247-D4DF519A-BA02-4278-95E7-B2EA59C0A4C6 Q33810499-164EA590-E02D-4A55-85AA-0B66F95C0E8B Q33965825-0BE985FA-549A-4B8B-A45D-B535B642984D Q33965898-A48631A9-D5C0-46C3-96D4-15BDC720CA6E Q33982467-989135BC-B265-4A3B-A932-166E7D2677E2 Q34352802-A0D97211-F7F6-4561-8BE3-A878258DA3B7 Q34650059-9799CBE7-9621-4DE8-9050-6A5D9ADE1728 Q34782487-516D5410-56F2-43D0-A4BD-FA825A84CC57 Q34840330-324D2537-1A47-4C1A-BD99-BC69235DD4E6 Q35115837-9DCF5CD6-90A0-4A29-94C4-C8ECE69DBAE7 Q35329940-8E5403F0-E450-4C47-ABA8-B1923CEBAC3A Q35533008-C49F1FB9-1636-4DD9-B414-4DAEDA1B18EA Q35662646-BC66467F-AED9-49D7-B0A4-EC2D368D1BB0 Q35673783-330E2E54-66A5-4839-9B83-FB333956D1FA Q35784429-0895A13D-799A-421F-8517-B34BC110944C Q35846126-A689DE26-8F1E-40E7-851A-F3B257D052D2 Q36306823-9577AC7D-C6E8-466B-84D4-D28B9B80AD45 Q36316309-663E3ED3-843D-42BB-9AAB-612E76D149EF Q36403201-FE16C54E-7832-4447-8D38-F6D127722725 Q36480359-72A08101-BD9E-43B1-89A2-CB67976A5735 Q36490514-91279EE0-B842-4533-AD52-D869E5B5358D Q36554724-1B2867FD-1E19-4D59-A53C-16FABF23A814 Q36755620-3888FE67-1B3D-40B3-856E-138BF5CA579F

P2860

Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

http://www.wikidata.org/entity/Q34035546

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Imatinib mesylate as add-on th ...... f the randomized IMPRES study.

@ast

Imatinib mesylate as add-on th ...... f the randomized IMPRES study.

@en

Imatinib mesylate as add-on th ...... f the randomized IMPRES study.

@nl

type

label

Imatinib mesylate as add-on th ...... f the randomized IMPRES study.

@ast

Imatinib mesylate as add-on th ...... f the randomized IMPRES study.

@en

Imatinib mesylate as add-on th ...... f the randomized IMPRES study.

@nl

prefLabel

Imatinib mesylate as add-on th ...... f the randomized IMPRES study.

@ast

Imatinib mesylate as add-on th ...... f the randomized IMPRES study.

@en

Imatinib mesylate as add-on th ...... f the randomized IMPRES study.

@nl

P1433

Q34035546-C5DB06C9-98BC-418F-AFA8-42B20A78C08D

P1476

Q34035546-D0FAD8F0-2707-4366-9BAD-CCAA3D457747

P2093

Q34035546-02313A7A-BDE6-4ED5-BA93-F3B55EB64C31

Q34035546-0AC006D8-8AF3-4CF5-843D-39817F67F7A0

Q34035546-13ED6CD0-5114-454D-BA3C-CD4A1F26D8F2

Q34035546-260AE6D6-688B-4236-A0C4-BBB9D61EDD5E

Q34035546-7C097D08-DADB-4AD3-A452-3B49EFB8D1DC

Q34035546-8A63B11A-CD2B-4B3D-8624-9E23A7EA5D5C

Q34035546-98A06AF9-04C2-48C5-960A-CD78C645FB0E

Q34035546-A8D5C91C-EF30-4F0E-AE3B-1A25F2DA60A2

Q34035546-B3EBB859-2C09-498D-BE8F-F78556D72EBC

Q34035546-CB19C515-7731-4528-8D67-D8ABABFAD1B4

P304

Q34035546-8901DEC3-95FB-4832-8442-FB43983665C5

P31

Q34035546-68BC6A1A-4276-4CAB-9D52-5986DE713D6F

P356

Q34035546-4B7016F2-AA2B-41F6-9D90-864AF4AD019C

P407

Q34035546-1A9B551C-4BD5-41B0-BB8D-FB347B0A1F19

P433

Q34035546-82C6282B-0A9B-48C3-84CF-A503D3FBE309

P478

Q34035546-C932F4A4-E9D8-4C72-9FB4-936A3E97239E

P50

Q34035546-4D6C91AA-9DAF-4C1A-9718-0D585A825FA6

Q34035546-A223C20A-238D-400B-8EC3-2C9E1F14258D

Q34035546-AC8B3672-7D4D-4097-80CD-798A35A8F033

Q34035546-B330FB61-268A-4BC5-B88D-C1680F92C508

Q34035546-C26EA063-CB28-4579-BE45-3AF3AC75A6FE

P577

Q34035546-AF4A86D1-3ED1-4F99-873F-3A82740A56B7

P698

Q34035546-90B68FB0-A6B4-4AB8-89E3-9191C9EB8472

P356

CIRCULATIONAHA.112.000765

P1433

P1476

Imatinib mesylate as add-on th ...... of the randomized IMPRES study

@en

P2093

Adaani E Frost

http://www.w3.org/2001/XMLSchema#string

Andrew J Peacock

http://www.w3.org/2001/XMLSchema#string

David Lawrence

http://www.w3.org/2001/XMLSchema#string

Deborah A Quinn

http://www.w3.org/2001/XMLSchema#string

Ekkehard Grünig

http://www.w3.org/2001/XMLSchema#string

Fernando Torres

http://www.w3.org/2001/XMLSchema#string

Gérald Simonneau

http://www.w3.org/2001/XMLSchema#string

Jeremy Feldman

http://www.w3.org/2001/XMLSchema#string

Miguel Angel Gómez-Sánchez

http://www.w3.org/2001/XMLSchema#string

Paul M Hassoun

http://www.w3.org/2001/XMLSchema#string

P304

1128-1138

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.112.000765

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P50

Marius M Hoeper

Friedrich Grimminger

Ardeschir Ghofrani

Nazzareno Galié

Nicholas W Morrell

P577

2013-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23403476

http://www.w3.org/2001/XMLSchema#string